IPO Calendar
Lead Manager
- J P Morgan Chase (490)
- Goldman Sachs (463)
- Morgan Stanley (421)
- Bank of America Merrill Lynch (358)
- Citigroup (222)
- Jefferies (214)
- Credit Suisse (180)
- Barclays (151)
- Cowen and Company (147)
- Deutsche Bank (84)
- Piper Jaffray (70)
- Leerink Partners (70)
- Stifel (65)
- UBS Investment Bank (53)
- Evercore (52)
- RBC Capital (51)
- BMO Capital (49)
- Wells Fargo (47)
- Raymond James (38)
- William Blair (37)
More +
IPO - Pricing (7)
Citigroup
| UnderWriters* | |||||||||||
| Date | Company Name | Sector | Price ($) |
Size (M) |
1 | 2 | 3 | Rank | Turnover | Gain | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Oct 27 | Myovant Science | Health-Care | 15 | 15 | BRCL | CITI | COWN | 37.8% | -11.6% | ||
| Oct 19 | CRISPR Therapeu | Health-Care | 14 | 4 | BRCL | CITI | PPRJ | 47.1% | 0.6% | ||
| Sep 23 | Valvoline Inc. | Basic-Industries | 22 | 30 | BAML | CITI | MS | 117.7% | 5% | ||
| Sep 21 | The Trade Desk | Technology | 18 | 4 | CITI | JEFF | RBC | 134.4% | 67.2% | ||
| May 26 | Reata Pharmaceu | Health-Care | 11 | 5 | CITI | COWN | 37.2% | 18.8% | |||
| May 19 | Merus N.V. | Health-Care | 10 | 5 | CITI | JEFF | GGNH | 18.7% | 0.4% | ||
| Mar 3 | Syndax Pharmace | Health-Care | 12 | 4 | CITI | MS | 43.6% | 0.1% | |||
*
Lead manager or one of top three managers in an underwriting team.